In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Concert Pharma (CNCE), with a price target of $23. The company’s shares closed yesterday at $10.59, close to its 52-week low of $9.21.
According to TipRanks.com, Yang is a 5-star analyst with an average return of 10.4% and a 41.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Concert Pharma has an analyst consensus of Strong Buy, with a price target consensus of $20, implying an 88.9% upside from current levels. In a report issued on May 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $26 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21 and a one-year low of $9.21. Currently, Concert Pharma has an average volume of 301.4K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CNCE in relation to earlier this year. Last month, Roger Tung, the CEO of CNCE bought 14,601 shares for a total of $55,338.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders.
